PMHNP Scope of Practice for ADHD in North Carolina

If you’re a psychiatrist or psychiatric nurse practitioner considering telehealth for ADHD treatment, you’ve probably asked yourself: Can I legally prescribe Adderall or other stimulants to a patient I’ve never met in person? The answer in 2026 is yes – but with important caveats that vary by state and provider type.

Here’s what you need to know about prescribing ADHD medications via telehealth right now, and what’s coming down the pipeline.

The Short Answer: Yes, Through December 2026

Thanks to federal extensions, you can currently prescribe Schedule II stimulants (Adderall, Ritalin, Vyvanse) via telehealth without an initial in-person exam through December 31, 2026. The DEA and HHS announced their fourth extension of COVID-era telehealth flexibilities in January 2026, giving providers and patients nearly another full year of certainty.

This applies to all Schedule II–V controlled substances for legitimate medical purposes, including ADHD medications. You need:

• A valid DEA registration and state medical/nursing license
• An audio-visual, real-time telehealth visit (video required – not just phone)
• Documentation that meets the standard of care for ADHD diagnosis
• Compliance with state-specific prescribing requirements (PDMP checks, e-prescribing, etc.)

But this is a temporary extension while the DEA finalizes permanent rules. So what happens in 2027?

Free consultations available with select providers only.

Grow your practice on Klarity

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

Start seeing patients

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

What’s Coming: The DEA’s New Telemedicine Framework

In January 2025, the DEA previewed three new telemedicine rules designed to make some COVID-era flexibilities permanent while adding patient safeguards. The key elements for ADHD prescribers:

Telemedicine Special Registration: The DEA is creating a new registration pathway that will allow providers to prescribe controlled substances to new patients via telehealth indefinitely – no in-person exam required. To qualify, you’ll need:

• A special DEA telemedicine registration (in addition to your standard DEA number)
• Mandatory nationwide PDMP checks before prescribing
• Strict patient identity verification during video visits
• Compliance with platform registration requirements (if you work through a telehealth company)

Established Patient Exception: If you’ve seen a patient in person at least once (or they’ve been seen by another provider in your practice), none of these new telemedicine restrictions apply. You can continue treating them remotely under standard prescribing rules.

What This Means Practically: Starting in 2027, if you want to treat ADHD patients entirely via telehealth without ever seeing them in person, you’ll likely need to obtain the special telemedicine registration. The DEA hasn’t published final rules yet, but this framework represents a middle ground between the pre-COVID restrictions (which essentially banned tele-prescribing of stimulants) and the wide-open flexibility of the past few years.

The DEA received over 38,000 public comments on earlier proposals – most from providers and patients arguing that requiring in-person visits after just 30 days would devastate continuity of care. They listened. The new rules aim to preserve access while preventing the ‘pill mill’ concerns that led to investigations of some telehealth startups.

State-by-State Reality: It’s Complicated

Federal law sets the floor, but states can add their own requirements. Here’s what you need to know about our six priority states for ADHD telehealth practice:

California: Wide Open for Telehealth

Bottom line: California explicitly allows telehealth exams to satisfy prescribing requirements – no in-person visit needed by state law.

For Psychiatrists (MD/DO): Full prescribing authority via telehealth. Check the CURES PDMP database before the initial prescription and every 4 months for ongoing stimulant therapy (state mandate).

For PMHNPs: California is transitioning to full practice authority for nurse practitioners. Experienced NPs (those who’ve completed 3 years or 4,600 hours under physician supervision) can now apply for independent practice status and prescribe ADHD medications without physician oversight. New grad NPs still need a supervising physician initially, but this changes by 2026 – making California one of the most NP-friendly states for telehealth psychiatry.

Licensing: You must hold a California license – the state isn’t part of the Interstate Medical Licensure Compact, and there’s no special telehealth registration for out-of-state providers.

Texas: Physicians Only for Stimulants

Bottom line: Texas allows telehealth for mental health treatment, but has a critical restriction for nurse practitioners.

For Psychiatrists: No state barriers to telehealth ADHD prescribing. Follow standard protocols, use video visits, document your evaluation. Texas doesn’t mandate PDMP checks specifically for stimulants (though it’s recommended).

For PMHNPs: Here’s the problem – Texas nurse practitioners cannot prescribe Schedule II controlled substances in outpatient settings. Period. The only exceptions are hospital inpatient orders (≥24 hours admission), hospice care, or ER medication orders. Outpatient ADHD treatment doesn’t qualify.

This means in Texas, only physicians (MD/DO) can write prescriptions for Adderall, Ritalin, or other stimulants. If you’re an NP practicing via a telehealth platform in Texas, you’ll need a physician collaborator to actually sign the prescription.

Why this matters: Many telehealth platforms use PMHNPs as their primary prescribers because there aren’t enough psychiatrists to meet demand. In Texas, this model doesn’t work for ADHD – you need MD/DO involvement, which limits scalability and increases costs.

Florida: Psychiatric Disorder Exception

Bottom line: Florida created an explicit carve-out for mental health prescribing via telehealth.

Florida law generally prohibits prescribing Schedule II controlled substances via telehealth, except for treatment of psychiatric disorders, inpatient care, hospice, or nursing homes. ADHD treatment falls under ‘psychiatric disorders,’ so you’re cleared to prescribe stimulants via telehealth.

For Psychiatrists: Full authority. Check the E-FORCSE PDMP before prescribing (state requirement for patients 16+).

For PMHNPs: Florida requires psychiatric NPs to work under a psychiatrist-supervised protocol, but they’re exempt from the 7-day supply limit that applies to other NPs prescribing Schedule II drugs. This means PMHNPs can write standard 30-day (or longer) stimulant prescriptions, not just week-long scripts.

Unique Florida Benefit: Out-of-state providers can register with Florida’s Department of Health to practice telehealth for Florida patients without getting a full Florida license (if they meet certain criteria: clean license, malpractice insurance, no disciplinary history). Since ADHD falls under the psychiatric exception, an out-of-state psychiatrist could see Florida patients via this registration pathway.

New York: Recently Aligned with Federal Rules

Bottom line: New York updated its regulations in May 2025 to explicitly allow controlled substance prescribing via telehealth in accordance with federal law.

Previously, New York mirrored the Ryan Haight Act’s in-person exam requirement. The May 2025 update removed that barrier, aligning state law with the DEA’s telehealth flexibilities.

For Psychiatrists: Full prescribing authority. You must check the I-STOP PMP registry before every Schedule II stimulant prescription (strictly enforced in NY). All controlled substance prescriptions must be electronic (mandatory since 2016).

For PMHNPs: New York allows NPs with over 3,600 hours of practice to work independently without a written collaborative agreement. They can prescribe ADHD medications with the same authority as physicians – no quantity limits specific to NPs.

Helpful NY Quirk: New York allows up to a 90-day supply of stimulants for ADHD if you note the prescription is for ‘minimal brain dysfunction’ or ADHD (code B on the prescription). Most states limit controlled substances to 30 days, so this is a practical advantage for stable telehealth patients – fewer refill appointments.

Pennsylvania: Collaboration Required for NPs

Bottom line: No state prohibition on telehealth prescribing, but NPs face limitations.

For Psychiatrists: Pennsylvania follows federal rules – no additional state barriers. Check the PA PDMP before initial controlled substance prescriptions (and periodically thereafter). Use electronic prescribing (mandatory for controlled substances since 2019).

For PMHNPs: Pennsylvania requires nurse practitioners to have a collaborative agreement with a physician. For Schedule II prescribing (stimulants), CRNPs are limited to 30-day supplies, and any continuation beyond 30 days requires physician approval.

In practice, this means your collaborating psychiatrist needs to review the case before you can refill a patient’s Adderall prescription beyond the first month. The physician doesn’t have to see the patient directly, but they must sign off on ongoing therapy – usually via monthly chart reviews.

Why this matters: If you’re an NP building a telehealth practice in PA, you need a physician partnership from day one. You can’t operate independently for ADHD treatment.

Illinois: Two-Tier System for NPs

Bottom line: Illinois allows telehealth prescribing and has created a pathway for NP independence – but not all NPs qualify.

For Psychiatrists: No state restrictions beyond federal requirements. Need an Illinois Controlled Substance License in addition to your DEA registration (administrative step, but mandatory).

For PMHNPs: Illinois has two tiers:

1. Collaborative Practice: NPs working under a physician collaborative agreement can prescribe Schedule II stimulants for up to 30 days. Any continuation requires physician approval. The physician must also review the NP’s Schedule II prescribing monthly.

2. Full Practice Authority (FPA): NPs who’ve completed 4,000 hours of collaborative practice and 250 hours of continuing education can apply for FPA status. FPA-certified NPs can prescribe stimulants independently without physician oversight or the 30-day limit – because stimulants are non-narcotic Schedule II drugs (the consultation requirement only applies to Schedule II narcotics and benzodiazepines).

Why this matters: If you’re recruiting PMHNPs in Illinois, experienced providers with FPA can operate like psychiatrists for ADHD treatment. Newer NPs need physician supervision similar to Pennsylvania’s model.

Comparison Table: State Rules at a Glance

The Business Case: Why These Rules Matter for Your Practice

Understanding these regulations isn’t just about staying compliant – it directly impacts your economics and patient volume.

Patient Acquisition Reality: Most providers don’t appreciate the true cost of acquiring psychiatric patients through traditional marketing channels:

• Google Ads for mental health keywords cost $15-40+ per click, and most clicks don’t convert to booked patients. Realistic cost per booked patient through PPC: $200-400+
• SEO takes 6-12 months of consistent investment before generating meaningful patient flow – and requires expertise most solo practitioners don’t have
• Directory listings (Psychology Today, Zocdoc) charge monthly fees AND you compete with hundreds of other providers. Zocdoc charges $35-100+ per booking, plus monthly subscription costs
• Agency/consultant fees for managing your marketing typically run $2,000-4,000/month, with no guaranteed results

When you factor in ALL costs – ad spend, agency fees, staff time to qualify leads, no-shows from cold inquiries, failed campaigns – acquiring a qualified psychiatric patient through DIY marketing typically costs $200-500+ per patient. And that’s if you have the budget to test and optimize campaigns for months.

The Telehealth Platform Alternative: Instead of gambling $3,000-5,000/month on marketing with uncertain ROI, platforms like Klarity use a pay-per-appointment model (similar to Zocdoc). You pay a standard listing fee only when a qualified patient books with you. The value proposition:

• No upfront marketing spend or monthly subscription fees
• Pre-qualified patients already matched to your specialty and availability
• No wasted ad spend on clicks that don’t convert
• Built-in telehealth infrastructure (no separate platform costs or IT headaches)
• Both insurance and cash-pay patient flow
• You control your schedule – only pay when you see patients

This is guaranteed ROI versus gambling on marketing channels where you might spend $5,000 and get three patients – or zero.

State Rules Impact Your Economics: Here’s why the state-by-state differences matter financially:

If you’re a PMHNP, you can practice independently in California and New York, but you’ll need physician partnerships in Texas, Pennsylvania, and Florida. That changes your practice model and overhead entirely.

For psychiatrists, Texas and Florida offer clear legal frameworks for telehealth ADHD prescribing, while Pennsylvania and Illinois defer to federal rules without adding state barriers. This regulatory clarity reduces compliance risk and makes it easier to scale your practice across state lines.

The platform model is especially attractive in restricted-practice states like Pennsylvania and Texas, where individual NPs can’t easily build solo ADHD practices due to collaboration requirements. A platform can handle the physician oversight infrastructure, letting you focus on patient care rather than administrative complexity.

Practical Compliance Checklist

If you’re prescribing ADHD medications via telehealth today, here’s what you need to have in place:

Federal Requirements (Through Dec 2026)

• [ ] Valid DEA registration
• [ ] Audio-visual (video) telehealth visit for initial evaluation – not just phone or questionnaire
• [ ] Documentation that meets standard of care for ADHD diagnosis (clinical interview, symptom assessment, ruling out other conditions)
• [ ] Electronic prescribing capability for controlled substances (EPCS)
• [ ] Follow usual course of professional practice and legitimate medical purpose

State-Specific Requirements

• [ ] License in the state where your patient is located during the visit
• [ ] PDMP/PMP check before prescribing (required in CA, NY, FL for stimulants; recommended in all states)
• [ ] State-specific controlled substance license if required (e.g., Illinois, New York)
• [ ] Compliance with state quantity limits if applicable (e.g., 30-day max for PA NPs)
• [ ] Physician collaborative agreement if required for your provider type (TX, PA, FL, IL for non-FPA NPs)

Best Practices (Not Legally Required, But Protect You)

• [ ] Patient consent for telehealth documented
• [ ] Identity verification process (photo ID check during video visit)
• [ ] Treatment agreement for controlled substances (especially for new patients)
• [ ] Regular monitoring for signs of misuse or diversion
• [ ] Clear emergency protocols if patient needs in-person care
• [ ] Documentation that explicitly notes you’re treating a psychiatric disorder (especially in states like Florida where this matters for legal authority)

What Happens After 2026?

The DEA’s permanent rules aren’t finalized yet, but based on their January 2025 announcement, here’s what’s likely coming:

If you want to continue prescribing ADHD meds to new patients via telehealth without in-person visits:

• Obtain the DEA Telemedicine Special Registration when available
• Implement whatever patient safeguards the final rule requires (likely nationwide PDMP checks, enhanced identity verification)
• Ensure your telehealth platform is also registered with the DEA (if required)

If you’re okay seeing patients in person at least once:

• No special registration needed – just follow standard prescribing rules
• The initial in-person visit establishes the relationship; you can continue via telehealth indefinitely

What this means strategically: The DEA is clearly moving toward a permanent telemedicine framework that preserves access. The agency received massive pushback when they initially proposed limiting telehealth prescribing to 30 days – patient advocacy groups, medical associations, and members of Congress all argued this would harm patients who rely on telehealth for ADHD treatment.

The special registration pathway is the DEA’s compromise: you can prescribe remotely, but you need extra credentials and must follow enhanced protocols to prevent abuse. For most legitimate providers, this is manageable compliance work, not a practice-ending restriction.

Why ADHD Telemedicine Isn’t Going Away

Despite the regulatory complexity, telehealth for ADHD treatment is here to stay for several reasons:

1. Provider shortage: There aren’t enough psychiatrists to meet demand, especially in rural areas. The American Psychiatric Association estimates the U.S. will face a shortage of 15,000-30,000 psychiatrists by 2030. Telehealth multiplies the reach of available providers.

2. Patient preference: Many patients prefer the convenience and reduced stigma of video visits. For working adults with ADHD, taking time off for in-person appointments every month creates barriers to treatment adherence.

3. Evidence base: Research during COVID showed telehealth ADHD treatment delivers comparable outcomes to in-person care, with high patient satisfaction. The clinical model works.

4. Political pressure: Both Republicans and Democrats support maintaining telehealth flexibilities. The DEA’s multiple extensions reflect bipartisan consensus that rolling back access would be politically and practically problematic.

5. State-level support: Most states have moved to support telehealth, not restrict it. Even cautious states like Texas and Pennsylvania haven’t added extra barriers beyond federal requirements.

The DEA knows it needs to balance access with abuse prevention. The special registration framework does that – it’s not perfect, but it’s workable.

FAQ: Common Provider Questions

Q: Can I prescribe ADHD medications after just an initial video visit, or do I need multiple sessions first?

A: Legally, you can prescribe after a single appropriate telehealth evaluation (through Dec 2026 under current rules). However, ‘appropriate’ is key – you need sufficient clinical information to make a diagnosis and rule out other conditions. Many providers do a comprehensive intake visit, then a follow-up to discuss treatment options, both via video. This both meets standard of care and reduces liability risk. Prescribing after a 15-minute video questionnaire would be risky practice, even if technically allowed by current federal rules.

Q: What if I’m licensed in State A but my patient is traveling in State B during our appointment?

A: You need to be licensed in the state where the patient is physically located at the time of the telehealth visit. If they’re vacationing in another state, you legally can’t treat them during that visit unless you also hold a license in that state. This is a known pain point for telehealth – patients can’t take their provider with them across state lines unless the provider has multi-state licenses.

Q: Do I need malpractice insurance that covers telehealth?

A: Yes. Most malpractice policies now include telehealth coverage, but verify with your carrier. Some older policies excluded telemedicine or required riders. Given the regulatory scrutiny on ADHD prescribing, make sure you’re covered.

Q: How often do I need to check the state PDMP – every prescription or just initially?

A: This varies by state:

• California: Initial check, then every 4 months
• New York: Every prescription (strictly enforced)
• Florida: Every prescription for patients 16+ (with limited exceptions)
• Pennsylvania, Illinois, Texas: Initial prescription at minimum; check periodically if you suspect misuse

Best practice: Check at initial evaluation and then every 3-6 months for ongoing treatment, or any time you have concerns about the patient’s medication use.

Q: Can I prescribe a 90-day supply of stimulants to reduce appointment frequency?

A: Depends on the state:

• New York: Yes, if you code the prescription for ADHD
• Most other states: Generally limited to 30 days for Schedule II controlled substances
• Check your state’s specific rules – some allow longer supplies for established, stable patients

Q: What happens if the DEA’s permanent rules are more restrictive than I expected?

A: The rules will be published in the Federal Register with a comment period before taking effect. That gives you time to prepare. If the final rules require an in-person visit at some point (e.g., after 6 months or annually), you’ll need to either: (1) see patients in person periodically, (2) refer them to an in-person provider for that visit, or (3) only treat patients via the special registration pathway. We’ll update our guidance as soon as final rules are published.

The Bottom Line

You can legally prescribe ADHD medications via telehealth right now, and that’s unlikely to change dramatically even after the DEA’s permanent rules take effect. The regulatory landscape is stabilizing around a framework that balances access with safety – not the wild west of 2020-2021, but not the pre-COVID prohibition either.

The key variables are your provider type and the states where you want to practice:

• Psychiatrists have the most flexibility across all states
• PMHNPs have full authority in California, New York, and Illinois (with FPA), but need physician partnerships in Texas, Pennsylvania, and Florida
• All providers need state licenses, PDMP checks, and proper documentation

For most psychiatrists and PMHNPs, the bigger barrier isn’t regulations – it’s patient acquisition. Building a sustainable telehealth practice requires either spending heavily on marketing with uncertain ROI, or partnering with a platform that handles patient flow.

If you’re tired of the marketing grind and want qualified ADHD patients matched to your schedule and expertise, Klarity offers a simpler path: you pay only when patients book, not for clicks that don’t convert or SEO campaigns that take a year to generate results. Our pre-qualified patient matching means you treat the patients you want to treat, without the wasted spend and guesswork of DIY marketing.

Ready to explore how Klarity’s provider network works? We handle the patient acquisition, compliance infrastructure, and platform technology – you focus on what you do best: treating patients and managing their care. Join Klarity’s provider network to see how our model compares to building a solo telehealth practice from scratch.

Sources and Citations

1. DEA & HHS Press Release – Extension of Telemedicine Flexibilities Through 2026 (January 2, 2026). Available at: https://www.hhs.gov/press-room/dea-telemedicine-extension-2026.html

2. Healthcare Dive – ‘DEA, HHS extend telehealth controlled substance prescribing flexibilities for fourth time’ by Emily Olsen (January 5, 2026). Available at: https://www.healthcaredive.com/news/dea-hhs-extend-telehealth-controlled-substance-prescriptions-flexibilities-fourth-time/808735/

3. DEA Press Release – ‘DEA Announces Three New Telemedicine Rules to Continue Open Access to Care’ (January 16, 2025). Available at: https://www.dea.gov/press-releases/2025/01/16/dea-announces-three-new-telemedicine-rules-continue-open-access

4. RxAgent Blog – ‘NP Prescriptive Authority by State: 2026 Guide’ (Last updated December 28, 2025). Available at: https://rxagent.co/blog/np-prescribing-authority

5. Texas Board of Nursing – APRN Practice FAQ regarding Schedule II prescribing limitations. Available at: https://www.bon.texas.gov/faqpracticeaprn.asp.html

6. Florida Statutes §456.47 – Telehealth prescribing of controlled substances (effective July 2019). Available at: https://www.leg.state.fl.us/statutes/index.cfm?Appmode=DisplayStatute&URL=0400-0499/0456/Sections/0456.47.html

7. Florida Statutes §464.012 – APRN prescribing authority and psychiatric nurse exemptions. Available at: https://www.leg.state.fl.us/statutes/index.cfm?Appmode=DisplayStatute&StatuteYear=2017&URL=0400-0499/0464/Sections/0464.012.html

8. New York State Department of Health – Bureau of Narcotic Enforcement Guidance on Prescribing Controlled Substances via Telehealth (May 21, 2025). Available at: https://www.ninthdistrict.org/home/2025/05/30/nysdoh-issues-guidance-on-prescribing-controlled-substances-via-telehealth

9. Pennsylvania Code Chapter 21 – CRNP Prescriptive Authority Regulations (Title 49, current through 2023). Available at: https://www.pacodeandbulletin.gov/secure/pacode/data/049/chapter21/chap21toc.html

10. Illinois Administrative Code – Nurse Practice Act Rules on APRN Prescribing (68 Ill. Adm. Code 1300, reflecting 2017 legislative changes). Available at: https://www.ilga.gov/agencies/JCAR/EntirePart?titlepart=06801300

11. Center for Connected Health Policy (CCHP) – State Telehealth Laws: Online Prescribing (Updated January 2026). Available at: https://www.cchpca.org/topic/online-prescribing/

All sources verified and accessed February 10, 2026. Regulatory information reflects current law as of publication date. Providers should verify requirements with their state medical boards and DEA for the most current guidance.

Source:

• https://www.healthcaredive.com/news/dea-hhs-extend-telehealth-controlled-substance-prescriptions-flexibilities-fourth-time/808735/#:~:text=,II%20to%20Schedule%20V%20drugs
• https://www.healthcaredive.com/news/dea-hhs-extend-telehealth-controlled-substance-prescriptions-flexibilities-fourth-time/808735/#:~:text=,to%20hash%20out%20permanent%20regulations
• https://rxagent.co/blog/np-prescribing-authority#:~:text=Proposed%20DEA%20rules%20create%20a,for%20telemedicine%20prescribing
• https://www.leg.state.fl.us/statutes/index.cfm?Appmode=DisplayStatute&URL=0400-0499%2F0456%2FSections%2F0456.47.html#:~:text=telehealth%20to%20provide%20health%20care,in%20Schedule%20II%20of%20s
• https://www.bon.texas.gov/faqpracticeaprn.asp.html#:~:text=there%20any%20settings%20other%20than,may%20prescribe%20Schedule%20II%20controlled
• https://www.ninthdistrict.org/home/2025/05/30/nysdoh-issues-guidance-on-prescribing-controlled-substances-via-telehealth#:~:text=as%20such%20terms%20are%20defined,the%20use%20of%20electronic%20prescribing
• https://www.pacodeandbulletin.gov/secure/pacode/data/049/chapter21/chap21toc.html#:~:text=,
• https://www.ilga.gov/agencies/JCAR/EntirePart?titlepart=06801300#:~:text=match%20at%20L5536%203,collaborating%20physician%20or%20podiatric%20physician
• https://rxagent.co/blog/np-prescribing-authority#:~:text=However%2C%20,3
• https://www.cchpca.org/topic/online-prescribing/#:~:text=Prescribing%2C%20dispensing%2C%20or%20furnishing%20dangerous,the%20appropriate%20standard%20of%20care